Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback